China Medical System Holdings Ltd - ESG Rating & Company Profile powered by AI
The report of China Medical System Holdings Ltd leverages information from across the internet as well as from public filings by China Medical System Holdings Ltd. The SDG score for China Medical System Holdings Ltd represents its transparency towards the UN SDGs. The report of China Medical System Holdings Ltd was prepared by All Street Sevva using advanced Cognitive Robots.
China Medical System Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.4; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.3.
0.4
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1924 | Sigma Healthcare Ltd | 0.5 | Low |
1924 | Uni-Bio Science Group Ltd | 0.5 | Low |
1952 | China Medical System Holdings Ltd | 0.4 | Low |
1952 | CFR Pharmaceuticals SA | 0.4 | Low |
1952 | CellSource Co Ltd | 0.4 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does China Medical System Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does China Medical System Holdings Ltd disclose current and historical energy intensity?
Does China Medical System Holdings Ltd report the average age of the workforce?
Does China Medical System Holdings Ltd reference operational or capital allocation in relation to climate change?
Does China Medical System Holdings Ltd disclose its ethnicity pay gap?
Does China Medical System Holdings Ltd disclose cybersecurity risks?
Does China Medical System Holdings Ltd offer flexible work?
Does China Medical System Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does China Medical System Holdings Ltd disclose the number of employees in R&D functions?
Does China Medical System Holdings Ltd conduct supply chain audits?
Does China Medical System Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does China Medical System Holdings Ltd conduct 360 degree staff reviews?
Does China Medical System Holdings Ltd disclose the individual responsible for D&I?
Does China Medical System Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does China Medical System Holdings Ltd disclose current and / or historical scope 2 emissions?
Does China Medical System Holdings Ltd disclose water use targets?
Does China Medical System Holdings Ltd have careers partnerships with academic institutions?
Did China Medical System Holdings Ltd have a product recall in the last two years?
Does China Medical System Holdings Ltd disclose incidents of discrimination?
Does China Medical System Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has China Medical System Holdings Ltd issued a profit warning in the past 24 months?
Does China Medical System Holdings Ltd disclose parental leave metrics?
Does China Medical System Holdings Ltd disclose climate scenario or pathway analysis?
Does China Medical System Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does China Medical System Holdings Ltd disclose the pay ratio of women to men?
Does China Medical System Holdings Ltd support suppliers with sustainability related research and development?
Does China Medical System Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does China Medical System Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is China Medical System Holdings Ltd involved in embryonic stem cell research?
Does China Medical System Holdings Ltd disclose GHG and Air Emissions intensity?
Does China Medical System Holdings Ltd disclose its waste policy?
Does China Medical System Holdings Ltd report according to TCFD requirements?
Does China Medical System Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does China Medical System Holdings Ltd disclose energy use targets?
Does China Medical System Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does China Medical System Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for China Medical System Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.